|
|
Post by Deb on Aug 5, 2005 12:02:23 GMT -5
Tovaxin™ is a novel T-cell therapeutic vaccine that parallels the concept of autologous cancer vaccines. Instead of modifying cancerous cells, TovaxinTM consists of attenuated autoreactive T cells. Attenuation of these cells during the vaccine production process renders the cells non-replicating but viable and causes them to elicit an immune response when injected subcutaneously into the patient. This immune response is directed against T cells within the patient that are self-reactive with myelin. This immune response, directed against a specific subset of autoreactive T cells, greatly reduces the number of these autoreactive cells in MS patients. TovaxinTM has considerable potential because it attacks the underlying cause of MS rather than just addressing its symptoms. more here> pharmafrontiers.net/toxavin.php |
|
|
|
Post by MSZany on Jun 12, 2007 18:29:31 GMT -5
Tovaxin™ is a novel T-cell therapeutic vaccine that parallels the concept of autologous cancer vaccines. Instead of modifying cancerous cells, TovaxinTM consists of attenuated autoreactive T cells. Attenuation of these cells during the vaccine production process renders the cells non-replicating but viable and causes them to elicit an immune response when injected subcutaneously into the patient. This immune response is directed against T cells within the patient that are self-reactive with myelin. This immune response, directed against a specific subset of autoreactive T cells, greatly reduces the number of these autoreactive cells in MS patients. TovaxinTM has considerable potential because it attacks the underlying cause of MS rather than just addressing its symptoms. more here> pharmafrontiers.net/toxavin.php |
|
